Mitchell C. Posner to Stomach Neoplasms
This is a "connection" page, showing publications Mitchell C. Posner has written about Stomach Neoplasms.
Connection Strength
3.944
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.589
-
For Gastroesophageal Junction Cancers, Does an "Esophageal" or "Gastric" Surgical Approach Offer Better Perioperative and Oncologic Outcomes? Ann Surg Oncol. 2020 Feb; 27(2):511-517.
Score: 0.575
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.444
-
Modern treatment of gastric gastrointestinal stromal tumors. World J Gastroenterol. 2012 Dec 14; 18(46):6720-8.
Score: 0.359
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Lancet Oncol. 2010 May; 11(5):404-5.
Score: 0.298
-
D3 or not D3... that is not the question. Lancet Oncol. 2006 Apr; 7(4):279-80.
Score: 0.225
-
The staging of gastric cancer: nothing novel but perhaps better. Ann Surg Oncol. 2003 Nov; 10(9):1005-6.
Score: 0.191
-
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.
Score: 0.157
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.156
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.125
-
Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg. 2014 Jan; 259(1):102-8.
Score: 0.096
-
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014 Jan; 149(1):18-25.
Score: 0.096
-
What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. Surgery. 2013 Nov; 154(5):1100-9.
Score: 0.095
-
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013 Aug; 217(2):347-57.e1.
Score: 0.092
-
Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. J Surg Oncol. 2013 Jun; 107(8):794-8.
Score: 0.091
-
Predictors of unsuccessful laparoscopic resection of gastric submucosal neoplasms. J Gastrointest Surg. 2013 Feb; 17(2):244-55; discussion 255-6.
Score: 0.090
-
A RAND/UCLA appropriateness study of the management of familial gastric cancer. Ann Surg Oncol. 2013 Feb; 20(2):533-41.
Score: 0.088
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.076
-
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66.
Score: 0.061
-
Efficacy of multimodality therapy in gastric adenocarcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):19-26.
Score: 0.023
-
Preemptive surgery for premalignant foregut lesions. J Gastrointest Surg. 2009 Oct; 13(10):1874-87.
Score: 0.018